Jazz Pharmaceuticals led the initial funding round for the startup, which aims to develop up to six drug candidates using the money.
US-based biopharmaceutical development company Arrivo BioVentures was launched yesterday with $49m of funding led by biopharmaceutical company Jazz Pharmaceuticals.
Jazz was joined in the initial funding round by Rex Health Ventures, the venture capital fund sponsored by healthcare system Rex Healthcare, as well as VC fund Solas BioVentures and undisclosed private investors.
Arrivo intends to develop between four and six drug candidates over the next five years and plans to find and acquire development-stage candidates that it can advance through…
